

DAFTAR PUSTAKA

- American Psychiatric Association (APA), 2000, *Diagnostic and Statistical Manual of Mental Disorder*, Fourth Edition, American Psychiatric Publisher, Washington.
- American Psychiatric Association (APA), 2004, *Practice Guideline for the Treatment of Patient with Schizophrenia* 2nd, American Psychiatric Publisher, Washington.
- Anil, Y.A.E., Kivircik A.B.B., Turgut, T.I., Tumuklu, M., Yazici, M.K., Alptekin, K., Ertugrul, A., Jayathilake, K., Gogus, A., Tunca, Z., dan Meltzer, H.Y., 2015, A double-blind controlled study of adjunctive treatment with risperidone in schizophrenic patients partially responsive to clozapine: efficacy and safety, *Journal of Clinical Psychiatry*, 66(1), 63-72.
- Anonim, 2015, *Keputusan Menteri Kesehatan Republik Indonesia Nomor Hk.02.02/Menkes/73/2015* tentang Pedoman Nasional Pelayanan Kedokteran Jiwa, Kementerian Kesehatan Republik Indonesia, Jakarta.
- Anonim, 2017, *Keputusan Menteri Kesehatan Republik Indonesia Nomor Hk.01.07/Menkes/659/2017* tentang Formularium Nasional, Kementerian Kesehatan Republik Indonesia, Jakarta.
- Arif, I. S., 2006, *Skizofrenia Memahami Dinamika Keluarga Pasien*, Refika Aditama, Bandung.
- Badan Penelitian dan Pengembangan Kesehatan, 2013, *Riset Kesehatan Dasar Republik Indonesia*, Kementerian Kesehatan Republik Indonesia, Jakarta.
- Badan Penelitian dan Pengembangan Kesehatan, 2018, *Riset Kesehatan Dasar Republik Indonesia*, Kementerian Kesehatan Republik Indonesia, Jakarta.
- Barnes, T.R., Paton, C., 2011, Antipsychotic polypharmacy in schizophrenia: benefits and risks, *CNS Drugs*, 25(5), 383-99.
- Bernardo, M., Coma, A., Ibáñez, C., Zara, C., Bari, J.M., dan Serrano-Blanco, A., 2012, Antipsychotic polypharmacy in a regional health service: a population based study, *BMC Psychiatry*, 12, 42.
- Budden, F. dan Sumerville, C., 2012, *Learning About Schizophrenia: Rays of Hope*, Fourth Ed., 4-22, Schizophrenia Society of Canada, Canada.
- Cascio, M.T., Cella, M., Preti, A., Meneghelli, A., dan Cocchi, A., 2012, Gender and duration of untreated psychosis: a systematic review and meta analysis, *Early Intervention in Psychiatry*, 6, 115-127.

- Correll, C.U. dan Gallego, J.A., 2012, Antipsychotic polypharmacy: a comprehensive evaluation of relevant correlates of a long-standing clinical practice, *Psychiatry Clinic North America*, 35(3), 661-681.
- Crismon, M.L., Agro, T.R. & Buckley, P.F., 2011, dalam DiPiro, J.T., Wells, B.G., Schwinghammer, T.L. & DiPiro, C.V., *Pharmacotherapy A Pathophysiological Approach*, Eighth Edition., 1147-1172, The McGraw-Hill Companies, New York.
- Crismon, M.L., Agro, T.R. & Buckley, P.F., 2015, dalam DiPiro, J.T., Wells, B.G., Schwinghammer, T.L. & DiPiro, C.V., *Pharmacotherapy A Pathophysiological Approach*, Ninth Edition, 731-746, The McGraw-Hill Companies, New York.
- Dong, M., Zeng, L.N., Zhang, Q., Yang, S.Y., Chen, L.Y., Sim, K., He, Y.L., Chiu, H.F.K., Sartorius, N., Tan, C.H., Chong, M.Y., Shinfuku, N., Lin, S.K., Ng, C.H., Ungvari, G.S. & Xiang, Y.T., 2019, Antipsychotic Polypharmacy in Older Adult Asian Patients with Schizophrenia: Research on Asian Psychotropic Prescription Pattern, *Journal of Geriatric Psychiatry and Neurology*, 32 (6), 304-311
- Fisher, M.D., Reilly, K., Isenberg, K. & Villa, K.F., 2014, Antipsychotic patterns of use in patients with schizophrenia: polypharmacy versus monotherapy, *BMC Psychiatry*, 14, 341.
- Freudenreich, O., Henderson, D.C., Walsh, J.P., Culhane, M.A. & Goff, D.C., 2007, Risperidone augmentation for schizophrenia partially responsive to clozapine: a double-blind, placebo-controlled trial, *Schizophrenia Research*, 92(1-3), 90-94.
- Gallego, J.A., Bonetti, J., Zhang, J., Kane, K.M. & Correll, C.U., 2012, Prevalence and correlates of antipsychotic polypharmacy: a systematic review and meta-regression of global and regional trends from the 1970s to 2009, *Schizophrenia Research*, 138(1), 18-28.
- Gibson, A.P., Patel, N.C., Lauriello, J., & Buckley, P.F., 2008, Antipsychotic combination blind step or logical ?, *Current Psychiatry*, 7 (7), 41-53.
- Goff, D.C. dan Coyle, J.T., 2001, The Emerging Role of Glutamate in The Pathophysiology and Treatment of Schizophrenia, *American Journal Psychiatry*, 158(9), 1367-1377.
- Gogos, A., Sbisa, A.M., Sun, J., Gibbons, A., Udawela, M. & Dean, B., 2015, A Role for Estrogen in Schizophrenia: Clinical and Preclinical Findings, *International Journal of Endocrinology*, Artikel ID 615356.
- Handayani, L., Febriani, R. & Saufi, A., 2015, Faktor Risiko Kejadian Skizofrenia di Rumah Sakit Jiwa Grhasia Daerah Istimewa Yogyakarta, *Humanitas*, 13(2), 135-148.

- Ih, H., Putri, R.A., dan Untari, E.K., 2016, Perbedaan jenis terapi antipsikotik terhadap lama rawat inap pasien skizofrenia fase akut di RSJD Sungai Bangkong Pontianak, *Jurnal Farmasi Klinik Indonesia*, 5 (2), 115-122.
- Ikawati, Zullies., 2011, *Farmakoterapi Penyakit Sistem Saraf Pusat*, 249-282, Bursa Ilmu, Jakarta.
- Jin, J., Sklar, G.E., Oh, V.M.S., dan Li, S.C., 2008, Factor affecting therapeutic compliance: A review from the patient's perspective, *Therapeutics and Clinical Risk Management*, 4(1), 269-286.
- Jones, H.M. dan Pilowsky, L.S., 2002, Dopamine and Antipsychotic Drug Action Revisited, *Britain Journal of Psychiatry*, 181(4), 271-275.
- Julaeha, J., Athiyah, U., dan Hermansyah, A., 2019, The second prescription pattern of second generation antipsychotics in schizophrenia outpatient setting, *Journal of Basic and Clinical Physiology and Pharmacology*, 30(6), 20190289.
- Karunakaran, K., Tungaraza, T.E. & Harborne, G.C., 2007, Isclopazine-aripiprazole combination a useful regimen in the management of treatment-resistant schizophrenia, *Journal Psychopharmacology*, 21(4), 453-456.
- Kelly, D.L., Borovicka, M. & Wehring, H.J., 2016. *Pharmacotherapy Principles & Practice* Fourth Edition, dalam Hafifah, A., Puspitasari, I.M., Sinuraya, R.K., 2018, Farmakoterapi dan Rehabilitasi Psikososial pada Skizofrenia, *Farmaka*, 16(2), 210-232.
- Kisely, S., Sawyer, E., Robinson, G., dan Siskind, D., 2015, A systematic review and meta-analysis of the effect of depot antipsychotic frequency on compliance and outcome, *Schizophrenia Research*, 166(1-3): 178-186.
- Lee, H.J., Kang, S.G., Cho, C.H., Choi, J.E., & Kim, L., 2008, Dopamine D2 receptor gene polymorphisms and tardive dyskinesia in schizophrenic patients, *Europe Neuropsychopharmacology*, 18, 210-221.
- Lemeshow, S., Hosmer, D.W., Klar, J. & Lwanga, S.K., 1990, *Adequacy of Sample Size in Health Studies*, 1-4, World Health Organization, England.
- Lim, S., Pralea, C., Schnitt, J., Bowers, M.B.Jr. & Cooper, C., 2004, Possible increased efficacy of low-dosed clozapine when combined with aripiprazole, *Journal Clinical Psychiatry*, 65(9), 1284-5.
- Mangarell, L.B., & Martinez, J.M., 2006, *Concise Guide to Psychopharmacology*, American Psychiatric Publishing, Washington DC.
- Marder, S.R., Van, P.T., Schatzberg, A.F. & Nemeroff, C.B., 1995, *Antipsychotic medications The American Psychiatric Press Textbook of Psychopharmacology*, 247-261, American Psychiatric Press, Washington DC.

- Miyamoto, S., Merrill, D.B., Lieberman, J.A., Fleischhacker, W.W., & Marder, S.R., 2008, *Antipsychotic drug* dalam Tasman, A., Kay, J., Lieberman, J.A., *etal.* (eds). *Psychiatry*, 3rd edition, 2161-2201, John Wiley & Sons, Chichester.
- Natari, R.B., Sukandar, E.Y., & Sigit, J.I, 2012, Antipsychotic Use Evaluation on First Episode Schizophrenic Patients at Jambi Psychiatric Hospital, **37**, 159–165.
- Notoatmodjo, S., 2007, *Promosi Kesehatan dan Ilmu Perilaku*, Rineka Cipta, Jakarta.
- Novitayai, S., 2016, Karakteristik pasien skizofrenia dengan riwayat rehospitalisasi, *Idea Nursing Journal*, 7 (2), 2087-2879.
- Okpataku, C.I. dan Tawani, D., 2017, Psycotropic prescription for the treatment of schizophrenia in an outpatient clinic, *Trends Psychiatry Psychother*, 39(3), 165-172.
- Perhimpunan Dokter Spesialis Kedokteran Jiwa Indonesia, 2011, *Konsensus Penatalaksanaan Gangguan Skizofrenia*, Jakarta.
- Permatasari, V.D., 2016, Pola Penggunaan Antipsikotik pada Pasien Skizofrenia di Instalasi Rawat Inap Rumah Sakit Jiwa Grhasia Yogyakarta Tahun 2014, *Skripsi*, Fakultas Farmasi Universitas Gadjah Mada, Yogyakarta.
- Rahaya, A. dan Cahaya, N., 2016, Studi Retrospektif Penggunaan Trihexylfenidil Pada Pasien Skizofrenia Rawat Inap yang Mendapat Terapi Antipsikotik di Rumah Sakit Jiwa Sambang Lihum, *Journal of Pharmacy*, 2 (2), 124-131.
- Sadock, B. J., Sadock, V. & Sussman, N., 2014, *Kaplan And Sadock's Pocket Handbook of Psychiatric Drug Treatment*, 233-235, Lippicott Williams and Wilkins, Philadelphia.
- Sadock, B.J., Sadock, V.A. & Ruiz, P., 2015, *Kaplan and Sadock's Synopsis of Psychiatry: Behavioral Sciences/Clinical Psychiatry*, Eleventh Edition, Wolter Kluwer, Philadelphia.
- Seeman, P., 1987, Dopamine Receptor and The Dopamine Hypothesis of Schizophrenia, *Synapse*, 1, 133-152.
- Weinbrenner, S., Assion, H.J., Stargardt, T., Busse, R., Juckel, G. & Gericke, C.A., 2009, Drug prescription patterns in schizophrenia outpatients: analysis of data from a German health insurance fund, *Pharmacopsychiatry*, 42(2), 66-71.
- Yazici, E., Cilli A.S., Yazici, A.B., Baysan, H., Ince, M., Bosgelmes, S., Bilgic, S., Aslan, B. & Erol, A., 2017, Antipsychotic Use Pattern In Schizophrenia Outpatients: Correlates Of Polypharmacy, *Clinical Practice And Epidemiology In Mental Health*, 13, 92-103.